Currently there is no pharmaceutical product approved for treating FSAD. NexMed is among the front-runners in the race to develop a viable treatment for FSAD.

Approximately 47 million American women are estimated to suffer from female sexual arousal disorder ("FSAD"), with symptoms that include the inability to experience sexual arousal or orgasm. The FSAD treatment market is projected to be a multibillion-dollar business opportunity, comparable in size, if not larger than the ED market. Currently there is no pharmaceutical product approved for treating FSAD. NexMed is among the front-runners in the race to develop a viable treatment for FSAD.

In addition to completing a U.S. Phase 2 study, we obtained positive results in a 400-patient Topical FSAD Treatment study conducted in China. The study was double-blind, placebo-controlled and randomized, and designed to test the efficacy and safety of the treatment in women diagnosed with female sexual arousal disorder (FSAD). The treatment is topically applied and incorporates alprostadil with the NexACT permeation enhancer. We are exploring partnering opportunities to co-develop a fast acting and convenient product.